23andMe Holding Co. (NASDAQ:ME) Short Interest Update

23andMe Holding Co. (NASDAQ:ME) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 950,200 shares, a drop of 16.6% from the November 15th total of 1,140,000 shares. Currently, 5.9% of the company’s shares are short sold. Based on an average daily volume of 325,600 shares, the days-to-cover ratio is presently 2.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ME. Geode Capital Management LLC grew its holdings in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in 23andMe by 410.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock valued at $35,000 after purchasing an additional 71,204 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in 23andMe during the 2nd quarter valued at $43,000. Levin Capital Strategies L.P. acquired a new stake in 23andMe during the 2nd quarter valued at $61,000. Finally, FMR LLC grew its holdings in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after purchasing an additional 192,099 shares in the last quarter. 36.10% of the stock is currently owned by hedge funds and other institutional investors.

23andMe Price Performance

23andMe stock opened at $3.35 on Friday. The stock’s 50-day moving average is $4.33 and its 200-day moving average is $6.61. The company has a market cap of $87.50 million, a price-to-earnings ratio of -0.13 and a beta of 1.15. 23andMe has a 12 month low of $2.65 and a 12 month high of $20.40.

23andMe (NASDAQ:ME) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter. The company had revenue of $44.07 million for the quarter, compared to analyst estimates of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.